查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
非甾体抗炎药市场规模、份额和趋势分析报告：按适应症（关节炎、偏头痛、眼科）、给药途径、分销渠道、地区、细分市场、预测 2022-2030
市场调查报告书
商品编码
1114027

非甾体抗炎药市场规模、份额和趋势分析报告：按适应症（关节炎、偏头痛、眼科）、给药途径、分销渠道、地区、细分市场、预测 2022-2030

Non-steroidal Anti-inflammatory Drugs Market Size, Share & Trends Analysis Report By Disease Indication (Arthritis, Migraine, Ophthalmic Diseases), By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2022 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

非甾体抗炎药的市场增长和趋势

Grand View Research, Inc. 的新报告显示，全球非甾体抗炎药市场在预测期内将以 5.36% 的复合年增长率增长，到 2030 年将达到 312.9 亿美元。预计达到美元。

非甾体抗炎药是主要用于缓解炎症和疼痛以及降低体温升高的药物。用于缓解经痛、头痛、发烧、关节炎、扭伤、紧张和其他慢性疼痛症状的非甾体抗炎药 (NSAID) 的高处方率预计将在预测期内推动市场增长。

由于全球范围内目标疾病和慢性疼痛的患病率上升以及这些疾病在老年人口中的流行等因素，非甾体抗炎药市场正在增长。预计将见证机会此外，对 OTC 非甾体抗炎药的需求增加，以及越来越多地采用非甾体抗炎药治疗头痛、偏头痛和月经来潮，预计也将推动预测期内的增长。

此外，关节炎和其他与疼痛相关的疾病日益流行也被认为是支持生长的一个因素。例如，英国、法国和德国的骨关节炎患病率高于欧洲其他地区。身体活动较多的人群中关节炎的患病率较低，并且其患病率似乎随着年龄的增长而增加。因此，预计关节炎患病率的上升也将有助于预测期内的增长。

主要市场参与者正在采取战略举措，例如地域扩张和引入非甾体抗炎药组合，以增加全球市场份额。此外，越来越多的非处方药用于疼痛管理和其他炎症性疾病的批准预计将支持预测期内的增长。因此，由于主要参与者采取的各种策略，预计市场将促进增长。

地区政府正在采取积极措施来减轻本国偏头痛和关节炎等疾病的负担。例如，美国国立卫生研究院启动了 HEAL 以加快研究工作，以改善疼痛和炎症性疾病的管理。此外，以患者为中心的结果研究所倡议引入非阿片类药物治疗疼痛的方案。预计这些努力将在预测期内提高增长率。

非甾体抗炎药市场报告亮点

2021 年，由于全球关节炎的高发率，关节炎部分主导了 NSAIDs 市场

零售药房占最大份额，预计在预测期内将保持主导地位

由于疼痛和相关疾病的高患病率、高患病率和老年人口增加等因素，预计亚太地区在预测期内的复合年增长率最高

p>

由于关节炎的高发率、主要市场参与者的存在以及该地区研究活动的增加，北美在 2021 年主导了市场。

内容

第一章调查方法及范围

  • 市场细分和范围
  • 调查方法
  • 信息采购
    • 购买的数据库：
    • GVR 内部数据库
    • 辅助信息
    • 初步调查
    • 初步调查的内容
  • 信息或数据分析
    • 数据分析模型
  • 市场製定和验证
  • 型号详情
    • 商品流向分析
      • 方法 1：商品流通方法
  • 辅助信息列表
  • 缩写列表
  • 目的

第 2 章执行摘要

  • 市场概览

第 3 章非甾体抗炎药市场变量、趋势和范围

  • 市场动态
    • 市场驱动因素分析
      • 不断增长的老年人口
      • 目标疾病的患病率增加
    • 市场约束分析
      • 与 NSAID 相关的副作用
  • 绘製渗透率和增长前景
  • 商业环境分析工具
    • SWOT 分析；按因素（政治和法律、经济和技术）
    • 波特五力分析
    • 行业分析 - Ansoph 矩阵
  • 价格分析
  • 监管场景

第四章监管与政治力量

  • 主要市场参与者的近期趋势和影响分析
    • 热图分析
  • 公司分类
    • 创新者
    • 市场领导者
  • 供应商情况
    • 主要分销商和渠道合作伙伴列表
    • 主要客户
    • 2021 年主要参与者的市场份额分析
  • 上市公司
    • 企业市场分析
      • 市场差异化因素
  • 私人公司
    • 主要初创公司列表
  • 分析重大交易和战略联盟
    • 推出新产品
    • 收购
    • 扩展名
    • 许可和合作伙伴关係

第 5 章非甾体抗炎药市场 - 细分分析，按疾病，2018-2030 年（百万美元）

  • 2021 年和 2030 年疾病适应症市场份额分析（百万美元）
  • 细分仪表板
  • 2018-2030 年市场规模和预测，趋势分析（百万美元）
    • 关节炎
    • 偏头痛
    • 眼科疾病
    • 其他

第 6 章非甾体抗炎药市场 - 细分分析，按给药途径，2018-2030 年（百万美元）

  • 2021 年和 2030 年行政失败市场份额分析（百万美元）
  • 细分仪表板
  • 2018-2030 年市场规模和预测、趋势分析（百万美元）
    • 口语
    • 主题
    • 其他

第 7 章非甾体抗炎药市场 - 细分分析，按分销渠道，2018-2030 年（百万美元）

  • 2021 年和 2030 年分销渠道市场份额分析（百万美元）
  • 细分仪表板
  • 2018-2030 年市场规模和预测、趋势分析（百万美元）
    • 医院药房
    • 零售药房
    • 在线药店

第 8 章非甾体抗炎药市场细分分析，按地区分列，2018-2030 年（百万美元）

  • 2021 年和 2030 年区域市场份额分析（百万美元）
  • 区域市场信息中心
  • 北美
    • 美国
  • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 西班牙
    • 法国
    • 意大利
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 澳大利亚
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东和非洲
    • 南非
    • 阿拉伯联合酋长国
    • 沙特阿拉伯

第 9 章竞争力和供应商格局

  • 参与者的分类
    • 创新者
    • 市场领导者
  • 战略规划
    • 该市场参与者选择的主要策略包括：
      • 推出新产品
      • 获取
      • 扩展名
      • 合同、合作和伙伴关係
      • 其他（重组、出售、市场渗透）：
  • 战略框架
    • 2021 年主要参与者的市场份额分析
  • 公司简介
    • 辉瑞公司
      • 公司简介
      • 财务表现
      • 产品基准
      • 战略举措
    • 拜耳公司
      • 公司简介
      • 财务表现
      • 产品基准
      • 战略举措
    • 葛兰素史克公司
      • 公司简介
      • 财务表现
      • 产品基准
      • 战略举措
    • 雷迪博士实验室有限公司
      • 公司简介
      • 财务表现
      • 产品线
      • 战略举措
    • Viatris Inc.
      • 公司简介
      • 财务表现
      • 产品线
      • 战略举措
    • 梯瓦製药工业有限公司
      • 公司简介
      • 产品基准
      • 战略举措
    • 强生服务公司
      • 公司简介
      • 财务表现
      • 产品基准
    • 默克公司
      • 公司简介
      • 财务表现
      • 产品基准
      • 战略举措
Product Code: GVR-4-68039-952-5

Non-steroidal Anti-inflammatory Drugs Market Growth & Trends:

The global non-steroidal anti-inflammatory drugs market is expected to reach USD 31.29 billion by 2030, expanding at a CAGR of 5.36% during the forecast period, according to a new report by Grand View Research, Inc. Nonsteroidal anti-inflammatory drugs are drugs that are primarily used to relieve inflammation and pain, as well as to lower elevated body temperature. The high prescription rate of non-steroidal anti-inflammatory drugs (NSAIDs) for relief of symptoms of painful periods, headaches, fever, arthritis, sprains, strains, and other types of chronic pain is expected to drive the market during the forecast period.

The non-steroidal anti-inflammatory drugs market is expected to witness growth opportunities owing to factors such as the rising prevalence of targeted diseases and chronic pain across the globe, coupled with the high prevalence of these diseases in the geriatric population. Moreover, increasing demand for OTC NSAIDs and the rising adoption of NSAIDs for headaches, migraines, and menstrual pain are also expected to boost the growth during the forecast period.

Moreover, the increasing prevalence of arthritis and other pain-related disorders is also expected to support the growth. For instance, the prevalence of osteoarthritis is higher in the UK, France, and Germany compared to other countries in the Europe region. The prevalence of arthritis is seen to be lower in people who are often engaged in physical activities, and its prevalence rises with age. Thus, the rising prevalence of arthritis is also expected to cater to the growth during the forecast period.

Key market players are adopting strategic initiatives such as geographical expansion and the introduction of combination non-steroidal anti-inflammatory drugs to increase their market share across the globe. For instance, Alkem Labs and Dr. Reddy's Laboratories Ltd have launched their non-steroidal anti-inflammatory drugs in the U.S. Moreover, increasing approval of OTC drugs for pain management and other inflammatory diseases is expected to drive growth during the forecast period. Thus, owing to the various strategies adopted by key players, the market is likely to boost its growth.

Governments in various regions are undertaking favorable initiatives to reduce the burden of migraine, arthritis, and other diseases in their countries. For instance, the National Institutes of Health has initiated HEAL to accelerate research activities to improve the management of pain and inflammatory diseases. Moreover, the Patient-Centered Outcomes Research Institute has undertaken initiatives to introduce non-opioid treatment options for pain. Such initiatives are expected to increase growth during the forecast period.

Non-steroidal Anti-inflammatory Drugs Market Report Highlights:

  • In 2021, the arthritis segment dominated the NSAIDs market owing to the higher prevalence of arthritis across the globe
  • The retail pharmacy segment held the largest share and is anticipated to maintain its dominance during the forecast period
  • Asia Pacific region is expected to witness the highest CAGR during the forecast period owing to factors such as the high prevalence of pain and related disorders, the high pool of patients, and a rising geriatric population across the region
  • North America dominated the market in 2021 due to the higher prevalence of arthritis, the presence of leading market players, and increased research activities within the region

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market Segmentation and Scope
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased Database:
    • 1.3.2 GVR's Internal Database
    • 1.3.3 Secondary Sources
    • 1.3.4 Primary Research
    • 1.3.5 Details of Primary Research
  • 1.4 Information or Data Analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity Flow Analysis
      • 1.6.1.1 Approach 1: commodity flow approach
  • 1.7 List of Secondary Sources
  • 1.8 List of Abbreviations
  • 1.9 Objectives
    • 1.9.1 Objective 1
    • 1.9.2 Objective 2
    • 1.9.3 Objective 3
    • 1.9.4 Objective 4

Chapter 2 Executive Summary

  • 2.1 Market Summary

Chapter 3 Non-Steroidal Anti-Inflammatory Drugs Market Variables, Trends & Scope

  • 3.1 Market Dynamics
    • 3.1.1 Market Driver Analysis
      • 3.1.1.1 Increasing Geriatric Population
      • 3.1.1.2 Increasing Prevalence of Targeted Diseases
    • 3.1.2 Market Restraint Analysis
      • 3.1.2.1 Side-effects Associated with NSAIDs
  • 3.2 Penetration and Growth Prospect Mapping
  • 3.3 Business Environment Analysis Tools
    • 3.3.1 SWOT Analysis; By factor (Political & Legal, Economic and Technological)
    • 3.3.2 Porter's Five Forces Analysis
    • 3.3.3 Industry Analysis - Ansoff Matrix
  • 3.4 Pricing Analysis
  • 3.5 Regulatory Scenario

Chapter 4 Regulatory & Political Forces

  • 4.1 Recent Developments & Impact Analysis, by Key Market Participants
    • 4.1.1 Heat map analysis
  • 4.2 Company Categorization
    • 4.2.1 Innovators
    • 4.2.2 Market Leaders
  • 4.3 Vendor Landscape
    • 4.3.1 List of key distributors and channel partners
    • 4.3.2 Key customers
    • 4.3.3 Key company market share analysis, 2021
  • 4.4 Public Companies
    • 4.4.1 Company market position analysis
      • 4.4.1.1 Market Differentiators
  • 4.5 Private Companies
    • 4.5.1 List of key emerging companies
  • 4.6 Major Deals and Strategic Alliances Analysis
    • 4.6.1 New Product Launch
    • 4.6.2 Acquisitions
    • 4.6.3 Expansion
    • 4.6.4 Licensing and Partnerships

Chapter 5 Non-Steroidal Anti-Inflammatory Drugs Market - Segment Analysis, By Disease indication, 2018 - 2030 (USD Million)

  • 5.1 Disease Indication Market Share Analysis, 2021 & 2030 (USD Million)
  • 5.2 Segment Dashboard
  • 5.3 Market Size & Forecasts and Trend Analysis, 2018 - 2030 (USD Million)
    • 5.3.1 Arthritis
      • 5.3.1.1 Arthritis market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.3.2 Migraine
      • 5.3.2.1 Migraine market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.3.3 Ophthalmic Diseases
      • 5.3.3.1 Ophthalmic diseases market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.3.4 Others
      • 5.3.4.1 Other market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 6 Non-Steroidal Anti-Inflammatory Drugs Market - Segment Analysis, By Route of Administration, 2018 - 2030 (USD Million)

  • 6.1 Route of Administration Market Share Analysis, 2021 & 2030 (USD Million)
  • 6.2 Segment Dashboard
  • 6.3 Market Size & Forecasts and Trend Analysis, 2018 to 2030 (USD Million)
    • 6.3.1 Oral
      • 6.3.1.1 Oral market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.3.2 Topical
      • 6.3.2.1 Topical market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.3.3 Others
      • 6.3.3.1 Other market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 7 Non-Steroidal Anti-Inflammatory Drugs Market - Segment Analysis, By Distribution Channel, 2018 - 2030 (USD Million)

  • 7.1 Distribution Channel Market Share Analysis, 2021 & 2030 (USD Million)
  • 7.2 Segment Dashboard
  • 7.3 Market Size & Forecasts and Trend Analysis, 2018 to 2030 (USD Million)
    • 7.3.1 Hospital Pharmacy
      • 7.3.1.1 Hospital pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.3.2 Retail Pharmacy
      • 7.3.2.1 Retail pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.3.3 Online Pharmacy
      • 7.3.3.1 Online pharmacy market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 8 Non-Steroidal Anti-Inflammatory Drugs Market - Segment Analysis, By Region, 2018 - 2030 (USD Million)

  • 8.1 Regional Market Share Analysis, 2021 & 2030 (USD Million)
  • 8.2 Regional Market Dashboard
  • 8.3 North America
    • 8.3.1 North America market estimates and forecast, 2018 - 2030 (USD Million)
    • 8.3.2 U.S.
      • 8.3.2.1 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
  • 8.4 Canada
    • 8.4.1. Canada market estimates and forecast, 2018 - 2030 (USD Million)
  • 8.5 Europe
    • 8.5.1 Europe market estimates and forecast, 2018 - 2030 (USD Million)
    • 8.5.2 Germany
      • 8.5.2.1 Germany market estimates and forecast, 2018 - 2030 (USD Million)
    • 8.5.3 UK
      • 8.5.3.1 UK market estimates and forecast, 2018 - 2030 (USD Million)
    • 8.5.4 Spain
      • 8.5.4.1 Spain market estimates and forecast, 2018 - 2030 (USD Million)
    • 8.5.5 France
      • 8.5.5.1 France market estimates and forecast, 2018 - 2030 (USD Million)
    • 8.5.6 Italy
      • 8.5.6.1 Italy market estimates and forecast, 2018 - 2030 (USD Million)
  • 8.6 Asia Pacific
    • 8.6.1 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
    • 8.6.2 Japan
      • 8.6.2.1 Japan market estimates and forecast, 2018 - 2030 (USD Million)
    • 8.6.3 China
      • 8.6.3.1 China market estimates and forecast, 2018 - 2030 (USD Million)
    • 8.6.4 India
      • 8.6.4.1 India market estimates and forecast, 2018 - 2030 (USD Million)
    • 8.6.5 South Korea
      • 8.6.5.1 South Korea market estimates and forecast, 2018 - 2030 (USD Million)
    • 8.6.6 Australia
      • 8.6.6.1 Australia market estimates and forecast, 2018 - 2030 (USD Million)
  • 8.7 Latin America
    • 8.7.1 Latin America market estimates and forecast, 2018 - 2030 (USD Million)
    • 8.7.2 Brazil
      • 8.7.2.1 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
    • 8.7.3 Mexico
      • 8.7.3.1 Mexico market estimates and forecast, 2018 - 2030 (USD Million)
    • 8.7.4 Argentina
      • 8.7.4.1 Argentina market estimates and forecast, 2018 - 2030 (USD Million)
  • 8.8 Middle East & Africa
    • 8.8.1 Middle East & Africa market estimates and forecast, 2018 - 2030 (USD Million)
    • 8.8.2 South Africa
      • 8.8.2.1 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
    • 8.8.3 UAE
      • 8.8.3.1 UAE market estimates and forecast, 2018 - 2030 (USD Million)
    • 8.8.4 Saudi Arabia
      • 8.8.4.1 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 9 Competitive & Vendor Landscape

  • 9.1 Participant Categorization
    • 9.1.1 Innovators
    • 9.1.2 Market Leaders
  • 9.2 Strategy Mapping
    • 9.2.1 Key Strategies Chosen by Players in this Market Include:
      • 9.2.1.1 Launch of new products
      • 9.2.1.2 Acquisition
      • 9.2.1.3 Expansion
      • 9.2.1.4 Agreements, collaborations, partnerships
      • 9.2.1.5 Others (realignment, divestment, market penetration):
  • 9.3 Strategic Framework
    • 9.3.1 Key Company Market Share Analysis, 2021
  • 9.4 Company Profiles
    • 9.4.1 Pfizer Inc.
      • 9.4.1.1 Company overview
      • 9.4.1.2 Financial performance
      • 9.4.1.3 Product benchmarking
      • 9.4.1.4 Strategic initiatives
    • 9.4.2 Bayer AG
      • 9.4.2.1 Company overview
      • 9.4.2.2 Financial performance
      • 9.4.2.3 Product benchmarking
      • 9.4.2.4 Strategic initiatives
    • 9.4.3 GSK plc
      • 9.4.3.1 Company overview
      • 9.4.3.2 Financial performance
      • 9.4.3.3 Product benchmarking
      • 9.4.3.4 Strategic initiatives
    • 9.4.4 Dr. Reddy's Laboratories Ltd
      • 9.4.4.1 Company overview
      • 9.4.4.2 Financial performance
      • 9.4.4.3 Product pipeline
      • 9.4.4.4 Strategic initiatives
    • 9.4.5 Viatris Inc
      • 9.4.5.1 Company overview
      • 9.4.5.2 Financial performance
      • 9.4.5.3 Product pipeline
      • 9.4.5.4 Strategic initiatives
    • 9.4.6 Teva Pharmaceutical Industries Ltd.
      • 9.4.6.1 Company overview
      • 9.4.6.2 Product benchmarking
      • 9.4.6.3 Strategic initiatives
    • 9.4.7 Johnson and Johnson Services, Inc.
      • 9.4.7.1 Company overview
      • 9.4.7.2 Financial performance
      • 9.4.7.3 Product benchmarking
    • 9.4.8 Merck & Co., Inc.
      • 9.4.8.1 Company overview
      • 9.4.8.2 Financial performance
      • 9.4.8.3 Product benchmarking
      • 9.4.8.4 Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 North America NSAIDs Market, By Country, 2018 - 2030 (USD Million)
  • Table 4 North America NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
  • Table 5 North America NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 6 U.S. NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
  • Table 7 U.S. NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 8 Canada NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
  • Table 9 Canada NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 10 Europe NSAIDs Market, By Country, 2018 - 2030 (USD Million)
  • Table 11 Europe NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
  • Table 12 Europe NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 13 U.K. NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
  • Table 14 U.K. NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 15 Germany NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
  • Table 16 Germany NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 17 France NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
  • Table 18 France NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 19 Spain NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
  • Table 20 Spain NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 21 Italy NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
  • Table 22 Italy NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 23 Asia Pacific NSAIDs Market, By Country, 2018 - 2030 (USD Million)
  • Table 24 Asia Pacific NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
  • Table 25 Asia Pacific NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 26 Japan NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
  • Table 27 Japan NSAIDs Market, By Route of Administration 2018 - 2030 (USD Million)
  • Table 28 China NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
  • Table 29 China NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 30 India NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
  • Table 31 India NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 32 South Korea NSAIDs Market, By Disease Indication 2018 - 2030 (USD Million)
  • Table 33 South Korea NSAIDs Market, By Route of Administration 2018 - 2030 (USD Million)
  • Table 34 Australia NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
  • Table 35 Australia NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 36 Latin America NSAIDs Market, By Country, 2018 - 2030 (USD Million)
  • Table 37 Latin America NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
  • Table 38 Latin America NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 39 Brazil NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
  • Table 40 Brazil NSAIDs Market, By Route of Administration 2018 - 2030 (USD Million)
  • Table 41 Mexico NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
  • Table 42 Mexico NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 43 Argentina NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
  • Table 44 Argentina NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 45 Middle East & Africa NSAIDs Market, By Country, 2018 - 2030 (USD Million)
  • Table 46 Middle East & Africa NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
  • Table 47 Middle East & Africa NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 48 South Africa NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
  • Table 49 South Africa NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 50 Saudi Arabia NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
  • Table 51 Saudi Arabia NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 52 UAE NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
  • Table 53 UAE NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 NSAIDs market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 NSAIDs market snapshot
  • Fig. 10 NSAIDs market driver impact
  • Fig. 11 NSAIDs market restraint impact
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 SWOT analysis, by a factor (political & legal, economic, and technological)
  • Fig. 14 Porter's five forces analysis
  • Fig. 15 Ansoff matrix
  • Fig. 16 NSAIDs market: Disease indication outlook and key takeaways
  • Fig. 17 NSAIDs market: Disease indication movement analysis
  • Fig. 18 Disease indication segment dashboard
  • Fig. 19 Arthritis market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 Migraine market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Ophthalmic diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Other market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 NSAIDs market: Route of administration outlook and key takeaways
  • Fig. 24 NSAIDs market: Route of administration movement analysis
  • Fig. 25 Route of administration segment dashboard
  • Fig. 26 Oral market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Topical market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Other market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 NSAIDs market: Distribution channel outlook and key takeaways
  • Fig. 30 NSAIDs market: Distribution channel movement analysis
  • Fig. 31 Distribution channel segment dashboard
  • Fig. 32 Hospital pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Retail pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 34 Online pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 NSAIDs market: regional outlook and key takeaways
  • Fig. 36 Regional outlook, 2021 & 2030 (USD Million)
  • Fig. 37 Regional market dashboard
  • Fig. 38 North America
  • Fig. 39 North America market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 40 U.S.
  • Fig. 41 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 42 Canada
  • Fig. 43 Canada market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 44 Europe
  • Fig. 45 Europe market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 46 Germany
  • Fig. 47 Germany market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 48 U.K.
  • Fig. 49 U.K. market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 50 Spain
  • Fig. 51 Spain market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 52 France
  • Fig. 53 France market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 54 Italy
  • Fig. 55 Italy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 56 Asia Pacific
  • Fig. 57 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 58 Japan
  • Fig. 59 Japan market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 60 China
  • Fig. 61 China market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 62 India
  • Fig. 63 India market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 64 South Korea
  • Fig. 65 South Korea market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 66 Australia
  • Fig. 67 Australia market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 68 Latin America
  • Fig. 69 Latin America market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 70 Brazil
  • Fig. 71 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 72 Mexico
  • Fig. 73 Mexico market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 74 Argentina
  • Fig. 75 Argentina market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 76 Middle East & Africa
  • Fig. 77 Middle East & Africa market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 78 South Africa
  • Fig. 79 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 80 UAE
  • Fig. 81 UAE market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 82 Saudi Arabia
  • Fig. 83 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 84 Participant categorization
  • Fig. 85 Strategy mapping
  • Fig. 86 Strategic framework
  • Fig. 87 Company market share analysis